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OBJECTIVES: The incretin mimetic exenatide improves glycae-
mic control with associated weight reduction in patients with type
2 diabetes (T2DM) treated with metformin (MET) and/or a
sulphonylurea (SU), or MET and/or a thiazolidinedione. As a
drug’s pharmacokinetics and pharmacodynamics can vary with
age, we explored exenatide’s efﬁcacy and safety for patients <65 y
and 65 y in this post-hoc analysis. METHODS: Patients com-
pleting 3 y of exenatide treatment on background therapies of
MET and/or an SU (N = 217, age 58  10 y, 64% male, weight
99  18 kg, HbA1c 8.2  1.0%, fasting plasma glucose [FPG]
9.6  2.5 mmol/L, diabetes duration 8  6 y; mean  SD)
had statistically signiﬁcant (P < 0.05) mean (SE) changes in
HbA1c (-1.0  0.1%), FPG (-1.3  0.2 mmol/L), and weight
(-5.3  0.4 kg). The two subgroups (baseline age <65 y, N = 161,
53  7 y, and65 y, N = 56, 70  4 y) differed in baseline dura-
tion of diabetes (7  6 y, 11  6 y). RESULTS: The mean
(SE) changes in HbA1c (-0.9  0.1%, -1.2  0.2%), weight
(-5.2  0.5 kg, -5.4  0.6 kg), and FPG (-1.1  0.3 mmol/L,
-1.8  0.3 mmol/L) were not statistically different for the two
subgroups (all, P > 0.1). In patients completing 3.5 y of exenatide,
changes in lipids for the <65 y subgroup (N = 118) and 65 y
subgroup (N = 33) were not statistically different, as follows
(mmol/L): HDL cholesterol (+0.21  0.02, +0.25  0.03), LDL
cholesterol (-0.28  0.09, -0.37  0.15), total cholesterol
(-0.26  0.09, -0.33  0.16), and triglycerides (-0.49  0.17,
-0.52  0.14) (all, P > 0.2). Nausea and hypoglycaemia, themost
common adverse events, occurred at similar rates in both sub-
groups. The only case of severe hypoglycaemia occurred in a
patient <65 y whose background therapies were MET and an SU.
CONCLUSION: In summary, in this open-label extension study
of T2DM patients treated with MET and/or an SU, exenatide
exposure 3 y resulted in similar safety proﬁles and improve-
ments in glycaemic control and lipid concentrations, with associ-
ated weight reductions for patients 65 y and <65 y.
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DATABASE ASSESSMENT OFTHE EFFECTIVENESS OF BRAND
VERSUS GENERIC ROSIGLITAZONE IN PATIENTS WITHTYPE
2 DIABETES MELLITUS
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OBJECTIVES: To compare the effectiveness of brand rosiglita-
zone maleate (BRM) versus generic rosiglitazone HCl (GRH) in
patients with type 2 diabetes mellitus, using computerized
records of a health care organization. METHODS: Comparison
of HbA1C reduction in patients starting treatment with either
BRM (n = 740) or GRH (n = 306) in the years 2004–2005.
RESULTS: BRM users were older (63.5  11 vs. 61.7  10 years
p < 0.001) and presented more cardiovascular disorders (38%
vs. 25%, p < 0.001) with no differences in gender distribution,
rates of hypertension or use of concomitant oral hypoglycemic
drugs. Use of concomitant insulin was more frequent (17.7% vs.
6.2%, p < 0.0001), rates of dispensed rosiglitazone doses
>4 mg/d (65.3% vs. 48.5%, p < 0.001) and treatment duration
was longer (9.3  6.2 vs. 5.2  2.2 months, p < 0.001) with the
generic formulation. Baseline HbA1C levels were higher
(9.0  1.5 vs. 8.6  1.2%, p < 0.001) and the absolute decrease
in HbA1C levels was greater in the GRH group (-1.2%  1.6%
vs. -0.5%  1.7%, p < 0.001). On multiple regression analysis,
the decrease in HbA1C (dependent variable) was associated
mainly with initial HbA1C level (partial r2 = 0.30). Rosiglita-
zone formulation (partial r2 = 0.02), age, treatment duration and
concomitant insulin (partial r2 = 0.006) were all signiﬁcant but
minor predictors, with no effect of rosiglitazone daily dose. Mean
regression-predicted decreases in HbA1C (with 95% CL) were
not signiﬁcantly different between the two rosiglitazone formu-
lations: -1.6% (-4.3% to +1.1%) for GRH and -1.1% (-3.8%
to +1.6%) for BRM. CONCLUSION: In this retrospective data-
base analysis, we found no evidence of different effectiveness of
generic vs. brand rosiglitazone in lowering HbA1C levels.
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ADDITION OF INHALED HUMAN INSULIN AS AN OPTION
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OBJECTIVES: The objective of this study was to compare the
rate of micro- and macrovascular complications in type 2 diabe-
tes mellitus (T2DM) patients, from increased insulin use due to
the addition of inhaled human insulin Exubera (EXU) as a treat-
ment option versus subcutaneous (sc) insulin alone using the
Economic Assessment of Glycemic Control and Long-term
Effects(Eagle) model. METHODS: The model included uncon-
trolled T2DM patients eligible for insulin. Long-term conse-
quences were based on risk equations derived from DCCT,
UKPDS and WESDR. The model used Freemantle’s estimates for
year one. In the arm where EXU and sc insulin were available,
43% of patients initiated insulin therapy (35% inhaled and 8%
sc insulin) versus 16% when only sc insulin was available. The
subsequent yearly increase in insulin uptake was based on data
from the DIN-LINK study. The model assumed 8% of patients
remained on sc insulin. RESULTS: The mortality rate observed
after 10 years was 34.5% versus 36.3% with inhaled and sc
insulin versus sc insulin respectively. Complications observed
after 10 years, when inhaled and sc insulin were available vs. sc
insulin alone, were 14.7% vs. 16.1% for myocardial infarction
and stroke, 5.2% vs. 5.9% for proliferative retinopathy, 43.4%
vs. 47.3% for microalbuminuria and 14.1% vs. 17.2% for
clinical neuropathy. In sensitivity analyses, EXU’s advantages
remained when insulin uptake was capped at 60% (i.e. always at
least 40% on OADs). CONCLUSION: Delaying insulin initia-
tion increases the rate of complications. The results showed that
when insulin use is increased due to the availability of inhaled
insulin, a reduction in all-cause mortality and the number of
complications should be observed. Exubera has the potential to
improve diabetes management by overcoming barriers to insulin
initiation in T2DM patients, and could help prevent more long-
term complications associated with T2DM.
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OBJECTIVES: The aim of this study was to determine if there
was an association between random blood glucose (RBG) obser-
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vations over a long period, and outcome in people with type 2
diabetes treated with insulin. METHODS: Data were extracted
from GPRD. An index of glucose variability was generated using
RBG observations over a sustained period (10 years from
insulin initiation) in subjects with 5 RBG observations using
the difference between the maximum and minimum RBG obser-
vation (DMax-MinRBG). Cox proportional hazards models were
developed characterising time to ﬁrst events for: acute myocar-
dial infarction (AMI), stroke, and severe visual loss, as well as for
all-cause mortality. Recognised vascular disease risk factors were
accounted for. RESULTS: There were 4238 subjects who met the
inclusion criteria. The subjects excluded were found to be more
poorly than those included, with shorter follow up and a greater
likelihood of having ever smoked. There was an association
between DMax-MinRBG and HbA1c whereby subjects with good
control were more like to have low variability. Following stan-
dardisation for potentially confounding factors, DMax-MinRBG
(m.mol/l) was associated with all-cause mortality (hazard
ratio [HR] = 1.026 per m.mol/l glucose; p = 0.020); stroke
(HR = 1.046; p < 0.001), and severe visual loss/blindness
(HR = 1.040; p = 0.025). For these three endpoints, DMax-MinRBG
was a better predictor of outcome than was HbA1c, whereas in
AMI, DMax-Min RBG was not signiﬁcant, and HbA1c was
(poor control versus good control: HR = 1.53; p = 0.034). CON-
CLUSION: Although we were unsure why general practitioners
were recording RBG observations, glucose variability over a
sustained period, as measured by DMax-MinRBG, was strongly
associated with all-cause mortality, stroke and vision loss in
people with type 2 diabetes treated with insulin, and more so
than was mean HbA1c over the same extended period.
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INDIRECT COMPARISON OF ONCE DAILY INSULIN DETEMIR
AND GLARGINE IN REDUCING WEIGHT GAIN AND
ACHIEVING GLYCEMIC CONTROL,WHEN ADMINISTERED IN
ADDITIONTO CONVENTIONAL ORAL ANTIDIABETIC
THERAPY INTHETREATMENT OFTYPE 2 DIABETES
PATIENTS;A META-ANALYSIS
Fakhoury W1, Lockhart I1, Kotchie R1, Le Reun C2,Aagren M3,
Nielsen S3
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OBJECTIVES: Basal insulin administered to type 2 diabetes
patients with poor glycemic control, when managed with oral
therapy alone, can lead to an increased risk of weight gain and
hypoglycemia. A meta-analysis of randomized controlled trials
(RCTs) using treat-to-target protocols was conducted to indi-
rectly compare insulin detemir with insulin glargine on the fol-
lowing outcomes: weight gain, hypoglycemic episodes, and
HbA1c. METHODS: Parallel-group RCTs of at least 20 weeks
duration that compared once-daily glargine or detemir with a
common comparator, NPH insulin (bedtime), in insulin-naïve,
poorly controlled type 2 diabetes patients receiving oral therapy,
were selected. Five open-label trials were identiﬁed (N = 2551
patients; N = 1 detemir and N = 4 glargine trials). A ﬁxed-effects
meta-analysis was used, with an indirect comparison of glargine
(N = 2047 patients) and detemir trials (N = 504 patients) carried
out using meta-regression. Weight gain and mean HbA1c change
from baseline were analyzed as weighted mean differences
(WMD). Mean Hba1c level at study endpoint was analyzed as
standardized mean differences (SMD), and total hypoglycemic
episodes per study were analyzed as odds-ratios (OR). Further
analyses were conducted which adjusted for covariates. Dosing
formulas were comparable across studies. RESULTS: Patients
receiving evening detemir gained signiﬁcantly less weight (unad-
justed WMD -1.22, 95% CI -2.15, -0.29; p = 0.010) and had a
signiﬁcantly lower total number of hypoglycemic episodes versus
evening glargine (unadjusted OR 0.52, 95% CI 0.28, 0.98;
p = 0.044). Mean change from baseline in HbA1c level favored
evening glargine, but there was no signiﬁcant difference between
treatments for mean HbA1c level at study endpoint (unadjusted
SMD 0.09, 95% CI -0.16, 0.33; p = 0.480). CONCLUSION:
Detemir appears similar to glargine in terms of achieving glyce-
mic control, but is superior to the latter for controlling weight
gain and reducing the incidence of hypoglycemic episodes in this
population.
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PRIMARY CARE PERSPECTIVE INTHE UNITED KINGDOM
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OBJECTIVES: In the UK, the role of insulin initiation has tradi-
tionally been one for specialist (secondary care) diabetes teams
(SDT) but this trend is changing. The increasing role of primary
care (PC) in diabetes management highlights the need for appro-
priate resource planning. This analysis describes the initial ﬁnd-
ings of a UK primary care audit of patients who were newly
initiated on insulin. METHODS: Data were collected from 8
primary care practices in the UK, covering a total of 58,452
people. Medical records were reviewed to ascertain the preva-
lence of type 2 diabetes mellitus (T2DM), those who initiated
insulin in the last 3 years and associated patient and treatment
details. RESULTS: A total of 2005 patients (3.4%) had a diag-
nosis of T2DM. Insulin was initiated in 316 patients with a mean
age at initiation of 63 years and duration of illness of 8 years. Of
these 149 had been initiated in the last three years (62% PC,
28% SDT) leading to an estimate of annual insulin initiations of
2.19% of all people with type 2 diabetes. The mean HbA1c
closest to insulin initiation was similar for PC (10.6%) and SDT
(10.4%) patients and 54% patients had BMI  30 kg/m2.
Patients commonly initiate insulin following two or more oral
medications (57%), the most common being metformin plus a
sulphonylurea. Pre-mixed insulins and long acting insulin ana-
logues were common, although use differed between PC (59%
long acting insulin analogues) and SDT (49% pre-mixed insulin).
CONCLUSION: In the UK, around 2% of people with T2DM
will be initiated on insulin annually. The majority of these are
initiated within a primary care setting and with HbA1c levels
which are above international clinical targets. Given the trend to
manage more diabetes in primary care, appropriate resources
need to be available to support patients through this intensiﬁca-
tion of therapy.
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ASSOCIATION BETWEENTOPICAL CORTICOSTEROID USE
AND DIABETES ONSET
Van der Linden MW1, Schalk BW1, Penning-van Beest FJA2,
Thomas VS3, Glendenning A4, Herings RMC2
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OBJECTIVES: To conﬁrm or refute a possible association
between intense Topical Corticosteroid (TC) use and new-onset
diabetes and establish whether it increases with dose and dura-
tion of TC use. METHODS: Data for this nested case-control
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